Alzheimer disease 1999: A status report

Alzheimer Disease and Associated Disorders

Volumn 13, Issue SUPPL. 1, 1999, Pages

  Kowall, Neil W ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Antiinflammatory; Antioxidant; Beta amyloid; Caregiver; Estrogen

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E4; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; ESTROGEN; IBUPROFEN; LAMININ; METRIFONATE; NERVE GROWTH FACTOR; PRESENILIN 1; PROTEINASE INHIBITOR; RIVASTIGMINE; SELEGILINE; TACRINE; VASOPRESSIN;

ALZHEIMER DISEASE; APOPTOSIS; BODY WEIGHT DISORDER; CAREGIVER; CLINICAL TRIAL; COMMUNITY CARE; DISEASE COURSE; DRUG COST; DRUG TOXICITY; EARLY DIAGNOSIS; GENE MUTATION; GENOTYPE; HUMAN; LONG TERM CARE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; NURSING HOME; OCCUPATION; OXIDATIVE PHOSPHORYLATION; PAIN; PALLIATIVE THERAPY; POINT MUTATION; PRIORITY JOURNAL; RACE; REVIEW; SENILE PLAQUE; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 0032875401     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199904001-00005     Document Type: Review

References (82)

1. Abbott RD, White LR, Ross GW, et al. Height as a marker of childhood development and late-life cognitive function: the Honolulu-Asia aging study. Pediatrics 1998;102:602-9.
2. AMA Council on Scientific Affairs Reference Committee D. Alzheimers disease. JAMA 1998;91:298-306.
3. Barinaga M. Is apoptosis key in Alzheimer's disease? Science 1998;281:1303-4.
4. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998;1366:211-23.
5. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-60.
6. Blass JP. Age-associated memory impairment and Alzheimer's disease. J Am Geriatr Soc 1996;44:209-11.
7. Blennow K, Vanmechelen E. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm Suppl 1998;53:223-35.
8. Bobinski M, de Leon MJ, Tarnawski M, et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res 1998;805:267-9.
9. Bowler JV, Munoz DG, Merskey H, Hachinski V. Factors affecting the age of onset and rate of progression of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998;65:184-90.
10. Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 1998;188:431-8.
11. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
12. Chandrasekaran K, Hatanpaa K, Brady DR, Stoll J, Rapoport SI. Down-regulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Brain Res 1998;796:13-9.
13. Chow N, Cox C, Callahan LM, Weimer JM, Guo L, Coleman PD. Expression profiles of multiple genes in single neurons of Alzheimer's disease. Proc Natl Acad Sci USA 1998;95:9620-5.
14. Clarke NJ, Tomlinson AJ, Ohyagi Y, Younkin S, Naylor S. Detection and quantitation of cellularly derived amyloid beta peptides by immunoprecipitation-HPLC-MS. FEBS Lett 1998;430:419-23.
15. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. Solution structure of amyloid beta-peptide (1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 1998;37:11064-77.
16. Davis KL. Future therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1998;59(suppl 11): 14-6.
17. De Leo ME, Borrello S, Passantino M, et al. Oxidative stress and over-expression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci Lett 1998;250:173-6.
18. de Leon MJ, Convit A, DeSanti S, et al. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int Psychogeriatr 1997;9(suppl 1):183-90; discussion 247-52.
19. Desgranges B, Baron JC, de la Sayette V, et al. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 1998;121:611-31.
20. Dumanchin C, Brice A, Campion D, et al. De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. J Med Genet 1998;35:672-3.
21. Duncan BA, Siegal AP. Early diagnosis and management of Alzheimer's disease. J Clin Psychiatry 1998;59(suppl 9): 15-21.
22. Eckman CB. Presenilins and Alzheimer's disease: the role of A beta 42. J Neurol Transm Suppl 1998;53:181-4.
23. Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:246-57.
24. Fiala M, Zhang L, Gan X, et al. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998;4:480-9.
25. Freeborough PA, Fox NC. MR image texture analysis applied to the diagnosis and tracking of Alzheimer's disease. IEEE Trans Med Imaging 1998;17:475-9.
26. Galasko D. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. J Neural Transm Suppl 1998;53:209-21.
27. Grundman M, Corey-Bloom J, Thai LJ. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J Neural Transm Suppl 1998;53:255-75.
28. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol 1998;24: 195-201.
29. Harper JD, Lieber CM, Lansbury PT Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol 1997;4:951-9.
30. Hock C, Golombowski S, Muller-Spahn F, et al. Histological markers in nasal mucosa of patients with Alzheimer's disease. Eur Neurol 1998; 40:31-6.
31. Hyman BT, Trojanowski JQ. Consensus recommendations for the post-mortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-7.
32. Ibarreta D, Urcelay E, Parrilla R, Ayuso MS. Distinct pH homeostatic features in lymphoblasts from Alzheimer's disease patients. Ann Neurol 1998;44:216-22.
33. Jellinger KA. The neuropathological diagnosis of Alzheimer disease. J Neural Transm Suppl 1998;53:97-118.
34. Juottonen K, Lehtovirta M, Helisahni S, Riekkinen PJ Sr, Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry 1998;65:322-7.
35. Keller JN, Mattson MP. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 1998;9:105-16.
36. Knapp M, Wilkinson D, Wigglesworth R. The economic consequences of Alzheimer's disease in the context of new drug developments. Int J Geriatr Psychiatry 1998;13:531-43.
37. Lakshmana MK, Rao BS, Dhingra NK, et al. Chronic (-)deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain. Brain Res 1998;796:38-44.
38. Lambert JC, Berr C, Pasquier F, et al. Pronounced impact of Th1/E47cs mutation compared with (-)491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet 1998;7:1511-6.
39. Lebert F, Pasquier F, Souliez L, Petit H. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516-9.
40. Leipzig RM. That was the year that was: an evidence-based clinical geriatrics update. J Am Geriatr Soc 1998;46:1040-9.
41. Licastro F, Davis LJ, Pedrini S, Galasko D, Masliah E. Prostaglandin E2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: implications for Alzheimer's disease. Biochem Biophys Res Commun 1998;249:182-6.
42. Maas ML, Specht JP, Weiler K, Buckwalter KC, Turner B. Special care units for people with Alzheimer's disease. Only for the privileged few? J Gerontol Nurs 1998;24(3):28-37.
43. Masliah E. Mechanisms of synaptic pathology in Alzheimer's disease. J Neural Transm Suppl 1998;53:147-58.
44. McKeith IG. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT). Dement Geriatr Cogn Disord 1998;9(suppl 2):2-7.
45. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease [letter] [see comments]. Nat Genet 1998;19:321-2.
46. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S13-21.
47. Monji A, Tashiro K, Yoshida I, Hayashi Y, Tashiro N. Laminin inhibits A beta 40 fibril formation promoted by apolipoprotein E4 in vitro. Brain Res 1998;796:171-5.
48. Monteiro IM, Boksay I, Auer SR, Torossian C, Sinaiko E, Reisberg B. Reliability of routine clinical instruments for the assessment of Alzheimer's disease administered by telephone. J Geriatr Psychiatry Neurol 1998;11:18-24.
49. Paykel ES, Huppert FA, Brayne C. Incidence of dementia and cognitive decline in over-75s in Cambridge: overview of cohort study. Soc Psychiatry Psychiatr Epidemiol 1998;33:387-92.
50. Peskind ER. Pharmacologic approaches to cognitive deficits in Alzheimer's disease. J Clin Psychiatry 1998;59(suppl 9):22-7.
51. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273:1274-8.
52. Polinsky RJ. Clinical pharmacology of rivastigmme: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47.
53. Preuss U, Mandelkow EM. Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. Eur J Cell Biol 1998;76:176-84.
54. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998;21:479-505.
55. Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998;44:288-91.
56. Roberto KA, Richter JM, Bottenberg DJ, Campbell S. Communication patterns between caregivers and their spouses with Alzheimer's disease: a case study. Arch Psychiatr Nurs 1998;12:202-8.
57. Rogaeva E, Premkumar S, Song Y, et al. Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 1998;280:614-8.
58. Sambamurti K, Lahiri DK. ERAB contains a putative noncleavable signal peptide. Biochem Biophys Res Commun 1998;249:546-9.
59. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336: 1216-22.
60. Schneider LS. New therapeutic approaches to cognitive impairment. J Clin Psychiatry 1998;59(suppl 11):8-13.
61. Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW. Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide. Brain Res 1998;796:187-97.
62. Sheng JG, Zhou XQ, Mrak RE, Griffin WS. Progressive neuronal injury associated with amyloid plaque formation in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:714-7.
63. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-50.
64. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998a;70:2212-5.
65. Smith MA, Sayre LM, Anderson VE, et al. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 1998b;46:731-5.
66. Song YQ, Rogaeva E, Premkumar S, et al. Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 1998;250:189-92.
67. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using Donepezil. Int J Geriatr Psychiatry 1998;13:445-53.
68. Tanaka T, Yamada K, Senzaki K, et al. NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats. Eur J Pharmacol 1998;352: 135-42.
69. Tang MX, Stem Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-5.
70. Tariot PN. Evaluating response to metrifonate. J Clin Psychiatry 1998;59(suppl 9):33-7.
71. Teplow DB. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 1998;5(2):121-42.
72. Thomas T, McLendon C, Thomas G. 1-Deprenyl: nitric oxide production and dilation of cerebral blood vessels. NeuroReport 1998;9: 2595-600.
73. Tomita T, Tokuhiro S, Hashimoto T, et al. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of ps2 with familial Alzheimer's disease mutation to increase secretion of abeta42. J Biol Chem 1998;273:21153-60.
74. van Leeuwen FW, Burbach JP, Hol EM. Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. Trends Neurosci 1998;21:331-5.
75. Vincent I, Zheng JH, Dickson DW, Kress Y, Davies P. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol Aging 1998;19:287-96.
76. Watson AA, Fairlie DP, Craik DJ. Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching? Biochemistry 1998;37:12700-6.
77. Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991;48:278-81.
78. Wegiel J, Wisniewski HM, Kuchna I, et al. Cell-type specific enhancement of amyloid-beta deposition in a novel presenilin-1 mutation (P117L). J Neuropathol Exp Neurol 1998;57:831-8.
79. Wisniewski HM, Silverman W. Diagnostic criteria for the neuropatho
80. logical assessment of Alzheimer's disease: current status and major issues. Neurobiol Aging 1997;18(suppl):S43-50.
81. Wu WS, Holmans P, Wavrant-DeVrieze F, et al. Genetic studies on chromosome 12 in late-onset Alzheimer disease. JAMA 1998;280:619-22.
82. Yallampalli S, Micci MA, Taglialatela G. Ascorbic acid prevents beta-amyloid-induced intracellular calcium increase and cell death in PC12 cells. Neurosci Lett 1998;251:105-8.